RENB
Price
$0.37
Change
-$0.01 (-2.63%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
60.54M
VRCA
Price
$0.46
Change
-$0.00 (-0.00%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
43.13M
12 days until earnings call
Ad is loading...

RENB vs VRCA

Header iconRENB vs VRCA Comparison
Open Charts RENB vs VRCABanner chart's image
Renovaro
Price$0.37
Change-$0.01 (-2.63%)
Volume$4.32K
Capitalization60.54M
Verrica Pharmaceuticals
Price$0.46
Change-$0.00 (-0.00%)
Volume$1.97K
Capitalization43.13M
RENB vs VRCA Comparison Chart
Loading...
RENB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RENB vs. VRCA commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RENB is a Hold and VRCA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (RENB: $0.37 vs. VRCA: $0.47)
Brand notoriety: RENB and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RENB: 59% vs. VRCA: 40%
Market capitalization -- RENB: $60.54M vs. VRCA: $43.13M
RENB [@Biotechnology] is valued at $60.54M. VRCA’s [@Biotechnology] market capitalization is $43.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RENB’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • RENB’s FA Score: 0 green, 5 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, both RENB and VRCA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RENB’s TA Score shows that 4 TA indicator(s) are bullish while VRCA’s TA Score has 5 bullish TA indicator(s).

  • RENB’s TA Score: 4 bullish, 3 bearish.
  • VRCA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both RENB and VRCA are a good buy in the short-term.

Price Growth

RENB (@Biotechnology) experienced а +5.73% price change this week, while VRCA (@Biotechnology) price change was -4.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

RENB is expected to report earnings on May 12, 2023.

VRCA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RENB($60.5M) has a higher market cap than VRCA($43.1M). VRCA YTD gains are higher at: -33.357 vs. RENB (-55.380). VRCA has higher annual earnings (EBITDA): -65.9M vs. RENB (-115.96M). VRCA has more cash in the bank: 46.3M vs. RENB (312K). RENB has less debt than VRCA: RENB (6.37M) vs VRCA (45.9M). VRCA has higher revenues than RENB: VRCA (7.57M) vs RENB (0).
RENBVRCARENB / VRCA
Capitalization60.5M43.1M140%
EBITDA-115.96M-65.9M176%
Gain YTD-55.380-33.357166%
P/E RatioN/AN/A-
Revenue07.57M-
Total Cash312K46.3M1%
Total Debt6.37M45.9M14%
FUNDAMENTALS RATINGS
RENB vs VRCA: Fundamental Ratings
RENB
VRCA
OUTLOOK RATING
1..100
574
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9794
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRCA's Valuation (96) in the Pharmaceuticals Major industry is in the same range as RENB (98) in the Financial Conglomerates industry. This means that VRCA’s stock grew similarly to RENB’s over the last 12 months.

VRCA's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RENB (100) in the Financial Conglomerates industry. This means that VRCA’s stock grew similarly to RENB’s over the last 12 months.

RENB's SMR Rating (97) in the Financial Conglomerates industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that RENB’s stock grew similarly to VRCA’s over the last 12 months.

VRCA's Price Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as RENB (97) in the Financial Conglomerates industry. This means that VRCA’s stock grew similarly to RENB’s over the last 12 months.

VRCA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RENB (100) in the Financial Conglomerates industry. This means that VRCA’s stock grew similarly to RENB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RENBVRCA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 11 days ago
87%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
RENB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VCIG4.730.73
+18.25%
VCI Global Limited
OLED125.456.97
+5.88%
Universal Display Corp
ETWO2.130.05
+2.40%
E2open Parent Holdings
COOK1.49-0.01
-0.67%
Traeger
MNST58.59-0.50
-0.85%
Monster Beverage Corp

RENB and

Correlation & Price change

A.I.dvisor indicates that over the last year, RENB has been loosely correlated with VRCA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if RENB jumps, then VRCA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RENB
1D Price
Change %
RENB100%
-0.75%
VRCA - RENB
37%
Loosely correlated
+1.70%
DTIL - RENB
36%
Loosely correlated
-3.17%
TNGX - RENB
34%
Loosely correlated
-0.68%
AAVXF - RENB
26%
Poorly correlated
N/A
QSI - RENB
26%
Poorly correlated
+4.27%
More

VRCA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with SCPX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then SCPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
+1.70%
SCPX - VRCA
38%
Loosely correlated
-8.70%
PBYI - VRCA
31%
Poorly correlated
-0.66%
ACOG - VRCA
31%
Poorly correlated
+2.85%
SLNO - VRCA
29%
Poorly correlated
+2.71%
FGEN - VRCA
29%
Poorly correlated
+4.40%
More